S-1: Bone Biologics Eyes $10.375 Million Capital Raise Through Stock and Warrant Offering

Bone Biologics Corporation is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common warrants, aiming to fund clinical trials and extend its patent portfolio.

Summary

• Bone Biologics Corporation is planning a public offering to sell shares of common stock along with warrants to purchase additional shares.
• The offering includes pre-funded warrants for investors who cannot exceed a certain ownership threshold, also bundled with warrants.
• The assumed combined public offering price is $ per share and accompanying warrant, with the warrants having an exercise price of $ per share.
• The company intends to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for general corporate purposes.
• The offering is being conducted on a best-efforts basis through a placement agent, with no minimum offering amount required.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol BBLG.
• The company has a limited operating history and has incurred losses since inception.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document contains both positive and negative aspects. The company is actively seeking funding and has a Nasdaq listing, but it also has a limited operating history, has incurred losses, and faces substantial competition. The auditor's doubt about the company's ability to continue as a going concern is a significant concern.

Positives

• The company is actively seeking funding to advance its clinical trials and intellectual property.
• The company's common stock is listed on the Nasdaq Capital Market.

Negatives

• The company has a limited operating history and has incurred losses since inception.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The offering is being conducted on a best-efforts basis, with no minimum offering amount required.
• Investors in this offering will experience immediate and substantial dilution in the book value of their investment.

Risks

• The company may be unable to comply with the continued listing standards of Nasdaq.
• The company's management will have broad discretion over the use of the proceeds from the offering.
• The company's product candidates are at an early stage of development and may not be successfully developed or commercialized.
• The company may be unable to obtain regulatory approval for its product candidates.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than the company does.
• The price of the company's common stock may fluctuate substantially.

Future Outlook

The company expects to need additional capital to fund its operations and continue to support its planned development and commercialization activities.

Industry Context

The medical device industry is characterized by rapidly evolving technology and intense competition. The company faces competition from major multi-national orthopedic and med-tech companies developing both generic and proprietary therapies to treat serious diseases.

Comparison to Industry Standards

• The company competes with large established orthopedic companies such as Medtronic, Stryker, Zimmer-Biomet, and DePuy-Synthes.
• These competitors possess considerably more resources than Bone Biologics.
• Many competitors have formed strategic collaborations, partnerships and other types of joint ventures with larger, well established industry competitors that afford these companies potential research and development and commercialization advantages in the therapeutic areas the company is currently pursuing.

Management Changes

Corporate Governance

Legal Proceedings

• On January 10, 2024 we entered into a Settlement Agreement and Mutual General Release (the Agreement) with Drs. Bessie (Chia) Soo and Kang (Eric) Ting, on the one hand (the plaintiffs), and the Company and Stephen LaNeve on the other hand (together with the Company, the defendants), in settlement of the claims for breach of contract and tortious interference with contract against the defendants filed in the United States District Court for the District of Massachusetts (the Court).
• Under the Agreement, we will pay the plaintiffs $750,000 in cash within 20 business days after the date the Agreement was executed.
• The parties to the Agreement have filed a joint stipulation to dismiss the action with prejudice with the Court and we expect the action to be dismissed by the Court.

Stakeholder Impact

• The company's ability to continue as a going concern is uncertain, which could impact stakeholders including shareholders, employees, and creditors.
• The company's success depends on obtaining regulatory approval for its product candidates, which could impact patients and healthcare providers.

Next Steps

• The company intends to use the pilot clinical trial data from Australia to enable a future larger U.S. pivotal clinical study, prior to submission of a PMA to the FDA.
• The company plans to carefully assess potential actions to regain compliance with the Nasdaq minimum bid price requirement.

Key Dates

Keywords

common stock, warrants, public offering, pre-funded warrants, clinical trials, Bone Biologics, NELL-1, capital raise